Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts

Bone Marrow Transplantation

Volumn 35, Issue 11, 2005, Pages 1055-1064

  Thirukkumaran, C M ^a   Luider, J M ^b   Stewart, D A ^a,c   Alain, T ^c   Russell, J A ^a,c   Auer, I A ^b   Forsyth, P ^c   Morris, Don G ^a,c  

^a TOM BAKER CANCER CENTRE   (Canada)

^b CALGARY LABORATORY SERVICES   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Autotransplantation; Breast cancer; Purging; Reovirus

Indexed keywords

CD34 ANTIGEN; ONCOLYTIC VIRUS;

APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW RESCUE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CONTAMINATION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REOVIRUS;

ANTIGENS, CD34; ANTIGENS, CD45; BLOOD COMPONENT REMOVAL; BONE MARROW PURGING; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA FRAGMENTATION; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METHIONINE; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRUSES;

EID: 20044365882     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704931     Document Type: Article

References (60)

1. Sandelin K, Apffelstaedt JP, Abdullah H et al. Breast surgery International - breast cancer in developing countries. Scand J Surg 2002; 91: 222-226.
2. Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424.
3. Broeders MJ, Verbeek AL. Breast cancer epidemiology and risk factors. Q J Nucl Med 1997; 41: 179-188.
4. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94: 2766-2792.
5. Nieto Y. The verdict is not in yet. Analysis of the randomized trial of high-dose chemotherapy for breast cancer. Haematologica 2003; 88: 201-211.
6. Roche H, Viens P, Biron P et al. High dose chemotherapy for breast cancer: The French PEGASES experience. Cancer Control 2003; 10: 42-47.
7. Antman KH. Randomized trials of high dose chemotherapy for breast cancer. Biochem Biophys Acta 2001; 1471 (3): M89-98.
8. Syme R, Steward D, Rodriguez-Galvez M et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003; 32: 307-311.
9. Heslop HE, Rill DR, Horwitz EM et al. Gene marking to assess tumor contamination in stem cell grafts for acute myelogenous leukemia. In: Dicke KA, Keating A (eds). Autologous Blood and Marrow Transplantation: Proceedings of the Ninth International Symposium. Arlington, TX, 1999, pp 513-520.
10. Deisseroth AB, Zu Z, Claxton D et al. Genetic markers shows that Ph+ cells present in autologous transplants of chonic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
11. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumours can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-383.
12. Lemoli RM, Gasparetto C, Scheinberg DA et al. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 1991; 77: 1829-1836.
13. Leung W, Cheng AR, Klann RC et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998; 22: 971-979.
14. Tsujino I, Anderson GS, Sieber F. Postirradiation hyperthermia selectively potentiates the merocyanine 540-sensitized photoinacitvation of small cell lung cancer cells. Photochem Photobiol 2001; 73: 191-198.
15. Brasseur N, Menard I, Forget A et al. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem Photobiol 2000; 72: 780-787.
16. Meck MM, Wierdl M, Wagner LM et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001; 61: 5083-5089.
17. Keir M, Fiddes R, Biggs JC, Kearney PP. Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections. Stem Cells 2000; 18: 422-427.
18. La Casse EC, Bray MR, Patterson B et al. Shiga like Toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34+ hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999; 94: 2901-2910.
19. Wu A, Mazumder A, Martuza RL et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res 2001; 61: 3009-3015.
20. Tyler KL, Fields BN. Reoviruses. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology. Lippincott-Raven: Philadelphia, 1996, pp 1597-1623.
21. Strong JE, Coffey MC, Tang D et al. The molecular basis of viral oncolysis: usurpation of the Ras signalling pathway by reovirus. EMBO J 1998; 17: 3351-3362.
22. Coffey MC, Strong JM, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated ras pathway. Science 1998; 282: 1332-1334.
23. Norman KL, Hirasawa K, Yang A et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathways dictates cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099-11104.
24. Wilcox ME, Yang W, Senger D et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001; 93: 903-912.
25. Hirasawa K, Nishikawa SG, Norman KL et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696-1701.
26. Norman KL, Coffey MC, Hirasawa K et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13: 641-652.
27. Nodwell M, Thirukkumaran C, Luider J et al. Reovirus as a novel prostate cancer therapeutic (abstract). Proc AACR 2000; 41: 122.
28. Alain T, Hirasawa K, Pon KJ et al. Reovirus therapy of lymphoid malignancies. Blood 2002; 100: 4146-4153.
29. Thirukkumaran CM, Luider JM, Stewart DA et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplants. Blood 2003; 102: 377-387.
30. Yang WQ, Senger DL, Lun XQ et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Therapy 2004, 1-11.
31. Smith RE, Zweerink H J, Jocklik WK. Polypeptide components of virions, top component and scores of reovirus type 3. Virology 1969; 39: 791-810.
32. Lee PW, Hayes EC, Joklik WK. Protein sigma 1 is the reovirus cell attachment protein. Virology 1981; 108: 138-163.
33. Keeney M, Chin-Yee I, Weir K et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998; 34: 61-70.
34. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD 34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
35. Farquhar C, Basser R, Hetrick S et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2003, CD00314 (available at: http://www.cochrane.org/cocharane/revabstr/AB003142.htm).
36. Farquhar C, Basser R, Marjoribanks J, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2003, CD003139 (available at: http://www.cochrane.org/cocharane/revabstr/AB003139.htm).
37. Datta YH, Adams PT, Drobyski WR et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 21: 475-482.
38. Peters WP, Shpall EJ, Jones RB et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1998; 6: 1368-1376.
39. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow matastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
40. Sharp JC, Kessinger A, Mann S. Detection and clinical significance of minimal tumour cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10 (Suppl): 92-94.
41. Franklin WA, Glaspy J, Plaumer SM et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999; 94: 340-347.
42. Nieto Y, Franklin WA, Jones RB et al. Prognostic significance of occult tumor cells in the aphersesis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 2004; 10: 415-425.
43. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
44. Kasimir-Bauer S, Mayer S, Bojko P et al. Survival of tumour cells in stem cell transplantations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose intensive or high-dose chemotherapy. Clin Cancer Res 2001; 7: 1582-1590.
45. Eckert LB, Repasky GA, Ulku A et al. Involvement of Ras activation in human breast cancer cell signalling, invasion and anoikis. Cancer Res 2004; 64: 4585-4592.
46. Garcia I, Dietrich PY, Aapro M et al. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 1989; 49: 6675-6679.
47. Rochlitz CF, Scott GK, Dodson JM et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989; 49: 357-360.
48. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
49. Ross JS, Flether JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3: 237-252.
50. Koenders PG, Beex LV, Geurts-Moespot A et al. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 1991; 51: 4544-4548.
51. Shackney SE, Pollice AA, Smith CA et al. Intracellular coexpresssion of epidermal growth factor receptor, Her-2neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin Cancer Res 1998; 4: 913-928.
52. Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res 1983; 43: 1696-1702.
53. Verbeek BS, Vroom TM, Adriaansen-Slot SS et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-388.
54. Cooper BW, Moss TJ, Ross AA et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patient with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-3517.
55. George A, Kost SI, Witzleben CL et al. Reovirus induced liver disease in severe combine immunodeficient (SCID) mice. A model for the study of viral infection, pathogenesis, and clearance. J Exp Med 1990; 171: 929-934.
56. Hirasawa K, Nishikawa S, Norman L et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 2003; 63: 348-353.
57. Morris DG, Forsyth PA, Patterson AH et al. A phase I clinical trail evaluating intralesional reolysin (reovirus) in histologically confirmed malignancies (abstract). ASCO 2002; 21: 24a.
58. Lillo R, Ramirez M, Alvarez A et al. Efficient and non-toxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Res 2002; 62: 5013-5018.
59. Hirai M, LaFace D, Robinson S et al. Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD 34+ cells. Cancer Gene Ther 2001; 8: 936-947.
60. Wagner LM, Guichard SM, Burger RA et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002; 62: 5001-5007.